Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 5/20 | 0.49 |
| ▸ | BACE1 | P56817 | 4/20 | 0.49 |
| ▸ | BCHE | P06276 | 3/20 | 0.49 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11413096 | 0.84 | FUCA1 (0.60) | ACHEBACE1BCHEFUCA1DRD2 | |
| SCHEMBL13102792 | 0.83 | FUCA1 (0.51) | KDM1AACHEBACE1BCHEFUCA1 | |
| SCHEMBL4619365 | 0.83 | FUCA1 (0.51) | KDM1AACHEBACE1BCHEFUCA1 | |
| SCHEMBL16837173 | 0.82 | FUCA1 (0.58) | ACHEBACE1BCHEFUCA1DRD2 | |
| SCHEMBL13853359 | 0.82 | ACHE (0.63) | ACHEBACE1BCHE | |
| SCHEMBL68520 | 0.81 | KDM1A (0.46) | KDM1AACHEBACE1BCHEFUCA1 | |
| SCHEMBL76455 | 0.81 | KDM1A (0.46) | KDM1AACHEBACE1BCHEFUCA1 | |
| SCHEMBL3212351 | 0.81 | ACHE (0.58) | ACHEBACE1BCHEFUCA1DRD2 | |
| SCHEMBL21737903 | 0.81 | ACHE (0.58) | ACHEBACE1BCHEFUCA1DRD2 | |
| SCHEMBL26709643 | 0.81 | ACHE (0.58) | ACHEBACE1BCHEFUCA1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131410-A1 | 3-AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| US-6559162-B2 | Electrophysiological activity | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| EP-1244631-A1 | NEW AZABICYCLOOCTANE DERIVATIVES USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-10-02 | — | — | EP | disclosed |
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
| WO-2001047893-A1 | NEW AZABICYCLOOCTANE DERIVATIVES USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | KCNH1, KCNH2, KCNH3 | KDM1A 1086/4885ACHE 2981/4885BACE1 4024/4885 |
| US-20090131410-A1 | 3-AZABICYCLOOCTANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM5 | KDM1A 1571/4885ACHE 129/4885BACE1 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.